Clinical Guidance for Smallpox Vaccine Use in a Postevent Vaccination Program

WB2559

Program Description:
The goal of this report is to provide recommendations that are intended to outline the clinical use of the three smallpox vaccines stored in the U.S. Strategic National Stockpile for persons who are exposed to smallpox virus or at high risk for smallpox infection during a post-event vaccination program following an intentional or accidental release of the virus.

Objectives:
Upon completion of this educational activity, the reader should be able to:
1. describe the basic natural history of smallpox virus infection,
2. describe the characteristics/properties of the three smallpox vaccines,
3. describe the basic public health and infection control measures used to control and prevent the transmission of smallpox virus,
4. describe the rationale and methods employed by CDC to develop the recommendations,
5. describe the populations, for whom smallpox vaccine is recommended,
6. describe the populations at high risk of adverse events from smallpox vaccine.

Faculty/Credentials:
Richard H. Beigi, MD, SMc, Physician, Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Inger K. Damon, MD, PhD, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC
Kathryn M. Edwards, MD, Director, Vanderbilt Vaccine Research Program, Vanderbilt University, Nashville, Tennessee
Margaret C. Fisher, MD, Medical Director, The Unterberg Children's Hospital at Monmouth Medical Center, Barnabas Health, Long Branch, New Jersey
Sharon E. Frey, MD, Professor of Internal Medicine, Center for Vaccine Development, Saint Louis University School of Medicine, Saint Louis, Missouri
Julie T. Guarnizo, BBA, Public Health Advisor, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC
Ruth Lynfield, MD, State Epidemiologist and Medical Director, Minnesota Department of Health, St. Paul, Minnesota
Dana Meaney-Delman, MD, MPH, Senior Medical Advisor for Preparedness, National Center for Emerging and Zoonotic Infectious Diseases, CDC
Carol A. Pertowski, MD, Senior Advisor, Office of the Director, Office of Public Health Preparedness and Response, CDC
Brett W. Petersen, MD, MPH, Medical Officer, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC
Rodney E. Willoughby, MD, Professor (Pediatrics) Children’s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin

ORIGINATION DATE: February 20, 2015

EXPIRATION DATE: February 20, 2017

URL: www.cdc.gov/mmwr

HARDWARE/SOFTWARE: Computer Hardware; Internet connection; Browser

MATERIALS: Access to internet

TARGET AUDIENCE: Physicians, Registered Nurses, Public Health Community

PREREQUISITES: Knowledge of the clinical use of the smallpox vaccines

FORMAT: Web-based, MMWR Journal

CONTACT INFORMATION: Brett Peterson at (404) 639-5464

ACCREDITATION STATEMENTS:

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this MMWR Journal for a maximum of (2) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides (1.9) contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer (0.2) CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to <2> total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number GA0082.

1.6.2015
For Certified Public Health Professionals (CPH)
CDC is an approved provider of CPH Recertification Credits by the National Board of Public Health Examiners. Effective October 1, 2013, the National Board of Public Health Examiners (NBPHE) accepts continuing education units (CEU) for CPH recertification credits from CDC. Please select CEU as your choice for continuing education when registering for a course on TCEOnline. Learners seeking CPH should use the guidelines provided by the NBPHE for calculating recertification credits. For assistance please contact NBPHE at http://www.NBPHE.org.

DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, our presenters content experts, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. Sharon Frey and she wishes to disclose that she has worked on several clinical trials for smallpox vaccines in the past that were funded by the current manufacturers of smallpox vaccines (i.e., Sanofi Pasteur and Bavarian Nordic) and by the NIH, received funding from the current smallpox vaccine manufacturers for past travel expenses to present at conferences and a training session, and will organize one study site for a clinical trial investigating Imvamune funded by the NIH and Bavarian Nordic. Following the workshop and during the writing of the guidance, Dr. Frey disclosed that she accepted an offer by Bavarian Nordic before initiation of guidance development to serve as the chair of a committee evaluating the ability of smallpox vaccine to induce a major or equivocal cutaneous reaction in participants of a clinical study.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Petersen’s, Dr. Damon’s and Dr. Lynfield’s discussion on two investigational smallpox vaccines. The report includes recommendations for two investigational smallpox vaccines that are anticipated to be used under emergency use authorization or investigational new drug protocols in the event of a declared public health emergency involving smallpox.

CDC does not accept commercial support.

To receive continuing education (CE):
Complete the activity
Complete the Evaluation at www.cdc.gov/TCEOnline
Pass the posttest at _70_____% at www.cdc.gov/TCEOnline

FEES: No fees are charged for CDC’s CE activities.

1.6.2015